Document is current
Any future updates will be listed below
-
Authors
Tseng, Chien-Yu https://orcid.org/0000-0001-7490-0077
Morris, Earl J. https://orcid.org/0000-0002-6092-8906
Sekhon, Vishaldeep K. https://orcid.org/0009-0009-5040-4402
Albrecht, Jennifer S. https://orcid.org/0000-0003-4838-2274
Wickwire, Emerson M. https://orcid.org/0000-0002-2858-7742
Spira, Adam P. https://orcid.org/0000-0003-1507-0995
Gross, Alden L. https://orcid.org/0000-0003-3276-2897
Malhotra, Atul https://orcid.org/0000-0002-9509-1827
Blinka, Marcela D. https://orcid.org/0000-0003-0369-9331
Kaufmann, Christopher N. https://orcid.org/0000-0002-2946-7857
-
Funding
Funding for this research was provided by:
National Institute on Aging (R01AG079391, K01AG061239, P30AG028740)
Sleep Research Society Foundation (23-FRA-001)
- License Information
-
More Information
Article History
Received: 9 January 2025
Revised: 19 March 2025
Accepted: 31 March 2025
First Online: 23 April 2025
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the University of Florida and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: This study was a secondary data analysis of publicly available data, and therefore, obtaining informed consent is not applicable.
: EMW’s institution has received research funding from the AASM Foundation, Department of Defense, Merck, NIH/NIA, ResMed, the ResMed Foundation, and the SRS Foundation. EMW has served as a scientific consultant to Axsome Therapeutics, DayZz, Eisai, EnsoData, Idorsia, Merck, Nox Health, Primasun, Purdue, and ResMed and is an equity shareholder in WellTap. APS has served as a scientific consultant to Merck, Sequoia Neurovitality, BellSant, Inc., and Amissa, Inc.
